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Abstract 
Background 
A few studies have shown that both quick Sequential Organ Failure Assessment (qSOFA) score and 
cell-free DNA (cfDNA) have potential use as a prognostic marker in patients with infection. We 
studied these two markers alone and in combination to identify those emergency department (ED) 
patients with the highest risk of death. 
Methods 
Plasma cfDNA level was studied on days 0 to 4 after admittance to the ED from 481 culture-positive 
bloodstream infection cases. The qSOFA score was evaluated retrospectively according to Sepsis-3 
definitions. The primary outcome was death by day 7. 
Results 
CfDNA on day 0 was significantly higher in non-survivors than in survivors (2.02 µg/ml vs. 1.35 
µg/ml, p<0.001). CfDNA level was high (>1.69 µg/ml) in 134 (28%) out of 481 cases and the qSOFA 
score was ≥2 in 128 (28%) out of 458 cases. High cfDNA and qSOFA score ≥2 had 70% and 77% 
sensitivity and 76% and 76% specificity in predicting death by day 7, respectively. High cfDNA alone 
had odds ratio (OR) of 7.7 (95% CI 3.9-15.3) and qSOFA score ≥2 OR of 11.6 (5.5-24.3), but their 
combination had OR of 20.3 (10.0-41.4) in predicting death by day 7 when compared with those with 
low cfDNA and qSOFA score <2. Among the five cases with the highest cfDNA levels, there were 
three patients with severe disseminated intravascular coagulation. 
Conclusion 
CfDNA and qSOFA score can be used independently to identify those bacteraemia patients at high 
risk of death, and combining these two markers gives additional advantage.  
Key words: biomarker; sepsis; bacteraemia  
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Introduction 
Cell-free plasma DNA (cfDNA), also called extracellular DNA, comprises fragments of DNA that are 
released from apoptotic and necrotic cells [1]. Elevated levels of cfDNA in blood have been found in 
various clinical conditions, such as cancer, trauma, stroke and sepsis [2-5]. A few studies have 
indicated that cfDNA may have value in predicting the mortality of sepsis patients in intensive care 
units (ICUs) [3, 6-11] and in emergency department (ED) patients [12, 13]. In recent years, cfDNA 
has also been found to have a role as a link between innate immunity and coagulation [14], and 
increased levels of cfDNA are found in patients with deep vein thrombosis [15]. To the best of our 
knowledge, no studies have evaluated cfDNA as a possible marker of disseminated intravascular 
coagulation (DIC). 
The criteria for sepsis were recently changed, and the quick Sequential Organ Failure Assessment 
(qSOFA) score has been introduced [16]. The qSOFA score was not invented to replace systemic 
inflammatory response syndrome (SIRS), but instead to help identify patients with suspected infection 
outside ICUs who are likely to develop complications [17, 18]. The qSOFA score has been shown to 
be better than SIRS as a prognostic marker of in-hospital mortality in an ED setting [19].  
In our earlier study, we evaluated 497 cases with blood culture-positive infection in the ED to 
establish how often death was related to sepsis and how often underlying diseases played a major role 
[20]. In the present study, we have measured plasma cfDNA in 481 of these blood culture-positive 
infection cases and evaluated the use of cfDNA as a prognostic marker in addition to the qSOFA 
score. We have also evaluated the possible association of high cfDNA to the clinical characteristics of 
bacteraemia. We used death by day 7 as a primary endpoint, since in our earlier study most of the 
sepsis-related deaths in patients with a prognosis of more than 6 months occurred early after 
admittance to the ED. Our secondary endpoint was death by day 28.  
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Methods 
Tampere University Hospital is a tertiary hospital situated in the Pirkanmaa region of Finland with a 
catchment population of approximately 524 700 inhabitants. Blood cultures are routinely taken from 
patients with signs or symptoms of systemic infection. As described in our previous study [20], blood 
culture-positive cases in the specialised care ED of Tampere University Hospital were selected during 
the period March 1, 2012 to February 28, 2014. In the present study, all cases with an available plasma 
sample for cfDNA analysis were included. The clinical data of the patients were gathered 
retrospectively. The primary and secondary endpoints were death by day 7 and 28, respectively.  
Blood cultures were collected in BacT/Alert Aerobic (FA Plus) and Anaerobic (FN Plus) blood culture 
bottles and placed in an automated microbial detection system BacT/Alert 3D (bioMérieux, Marcy 
l’Etoile, France). All culture-positive cases were selected by a clinical microbiologist. Cultures 
positive for coagulase-negative Staphylococcus, Propionibacterium, Bacillus, Micrococcus and 
Corynebacterium, with detection in a single blood culture bottle and without clinical relevance, were 
considered to be contaminants and were excluded. Also, positive samples were excluded if the first 
routine blood sample within the first 24 hours after the blood culture collection (day 0) was missed. 
This could be because the culture became positive later than 72 hours after admission. 
The level of plasma cfDNA was analysed from blood samples from days 0 to 4. The day 0 sample was 
gathered mostly at the same time as the collection of the blood cultures, but samples gathered within 
24 hours of the collection were included. Qubit dsDNA HS Assay Kit and Qubit 2.0 fluorometer 
(Invitrogen, Carlsbad, CA, USA) were used for quantification of plasma cfDNA. The manufacturer’s 
instructions and protocols were followed at each step. After plasma extraction, the turnaround time 
spent on the laboratory analysis of cfDNA level was approximately 10 minutes. The intra-assay 
coefficients of variation from control samples were between 3.55% and 5.73%. The final result was 
the average of the two samples. 
Diagnoses of sepsis, severe sepsis and septic shock were made according to Sepsis-2 consensus 
definitions [21]. A criterion for qSOFA score was calculated based on Sepsis-3 definitions [16]. The 
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qSOFA score comprises the following criteria: altered mentation, respiratory rate ≥22 and systolic 
blood pressure ≤100 mmHg. In this study, altered mentation was classified based on the verbal section 
of the Glasgow Coma Scale: if the patient had less than 5 points in this section, the patient was 
considered to have altered mentation. The Pitt Bacteraemia Score was calculated as presented by 
Korvick et al. [22].  
IBM SPSS version 22.0 software (IBM Corp., Armonk, NY, USA) was used for the statistical 
analyses. A p-value of <0.05 was considered significant. Nonparametric data were analysed by Mann-
Whitney U Test or Kruskall Wallis test when appropriate. The Youden index was used to select 
optimal cut-off analysis. Predictive performance (accuracy) of the cfDNA level and qSOFA score was 
assessed using the AUC/ROC statistic. A logistic regression model was used to study the independent 
effect of high cfDNA level on mortality models adjusted for potential confounders. The survival curve 
was assessed using the Kaplan-Meier method, and survival differences between groups were 
compared by log-rank test. The study was approved by the Ethics Committee of Tampere University 
Hospital and the National Supervisory Authority for Welfare and Health. The need for informed 
consent was waived as no additional blood sampling was needed and routine patient care was not 
modified. 
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Results 
There were 800 consecutive positive blood cultures during the study period. Contaminants (n=136) 
were excluded and 167 blood cultures were excluded for missing the blood sample from day 0. The 
first sixteen of the gathered samples went missing later. A total of 481 cases among 469 patients were 
thus included. There were 253 (53%) male cases, 228 (47%) female cases, all were adults (>16 years), 
and the median age was 68 years. Table 1 provides information on patient characteristics, clinical 
presentation and microbiology of the infection. 
The minimum cfDNA level on day 0 to day 4 was 0.72 µg/ml, and the maximum was 66.95 µg/ml. 
The mean level on day 0 was 1.73 µg/ml, and the median was 1.38 µg/ml. Table 2 and Figure 1 show 
levels of cfDNA during days 0 to 4 in all cases and in relation to death by day 7. CfDNA day 0 levels 
in the non-survivors were significantly higher compared with survivors. Furthermore, levels remained 
at a significantly higher level on day 1 to day 4.  
The optimal cut-off value for the plasma cfDNA values on day 0 in predicting death by day 7 was 
estimated using ROC curve, as illustrated in Figure 2. CfDNA had an AUC of 0.77 (95%CI 0.69 to 
0.85) in predicting death by day 7. A cut-off value of 1.69 µg/ml had sensitivity of 70.4% and 
specificity of 76.4% in predicting death by day 7 with an AUC of 0.73 (95% Confidence Interval (CI) 
0.65 to 0.82, p<0.001). Plasma cfDNA levels above this cut-off value are hereafter referred to as high 
and levels below this value are referred to as low. CfDNA level was high in 134 (28%) out of 481 
cases, and qSOFA score was ≥2 in 128 (28%) out of 458 cases. A comparison of high cfDNA and 
qSOFA score ≥2 in relation to death by day 7 is given in Table 3. QSOFA score ≥2 together with high 
cfDNA level on day 0 resulted in a 20-fold risk of death by day 7, when compared with those with low 
cfDNA level and qSOFA score <2. Odds ratios of death by day 7 were 7.7 (95% CI 3.9 to 15.3) and 
11.6 (95% CI 5.5 to 24.3) for high vs. low cfDNA and qSOFA score ≥2 vs. qSOFA score <2, 
respectively (Table 3). Figure 3 presents the Kaplan-Meier survival curves by day 28 for high cfDNA, 
qSOFA score ≥2 and both.  
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Death by day 28 was a secondary endpoint. CfDNA on day 0 was significantly higher in non-survivors 
than in survivors (1.95 µg/ml vs. 1.33 µg/ml, p<0.001). CfDNA had an AUC of 0.76 (95%CI 0.69 to 
0.82) in predicting death by day 28. The optimal cut-off value of cfDNA in predicting death by day 28 
was the same as in death by day 7 (1.69 µg/ml). The results for the secondary endpoint (day 28) are 
shown in Table 3.  
The maximum level of cfDNA at day 0 was 38.85 µg/ml and in this patient it remained between 29.50 
µg/ml and 66.95 µg/ml on days 1 to 4. This patient suffered from a severe pneumococcal infection 
with DIC resulting in multiple amputations. Among the five highest cfDNA levels at day 0, there were 
two other patients with DIC caused by Capnocytophaga canimorsus sepsis that resulted in skin 
necrosis or amputations. Their cfDNA levels were 9.65 µg/ml and 8.92 µg/ml.  
Median level of cfDNA at day 0 in cases with qSOFA score <2 was 1.34 µg/ml (Inter-Quartile Range 
(IQR) 1.16 µg/ml to 1.64 µg/ml). Ten patients with qSOFA score <2 died by day 7 with the median 
day 0 cfDNA level of 1.45 µg/ml (IQR 1.38 µg/ml to 1.90 µg/ml). The difference of day 0 cfDNA 
level between survivors and non-survivors in patients with qSOFA score <2 was statistically 
insignificant (p=0.10). C-reactive protein (CRP) level on day 0 did not have a significant predictive 
value for death by day 7 (AUC 0.52 (95% CI 0.43 to 0.60), p=0.677, data on 478 cases). In predicting 
transfer to ICU within 24 hours of admission, cfDNA level had an AUC of 0.70 (95% CI 0.61 to 0.80, 
p<0.001) and qSOFA score ≥2 0.72 (0.63 to 0.80, p<0.001). 
Table 4 presents the day 0 plasma cfDNA levels stratified by various demographic features, 
underlying conditions and severity of sepsis. The level of cfDNA was statistically significantly higher 
in the following conditions: liver disease, alcohol abuse, septic shock, admitted from ED to ICU, Pitt 
Bacteraemia Score ≥4 and death by day 7 or day 28. The level of cfDNA was statistically significantly 
lower in patients with hematologic cancer. 
Statistically significant variables associated with death by day 7 in univariate analysis were 
cardiovascular disease, liver disease, alcohol abuse, MRSA carriage, Pitt Bacteraemia Score ≥4, high 
cfDNA, qSOFA score ≥2 and both qSOFA score ≥2 and high cfDNA. The following variables were 
8 
 
not associated with death by day 7: sex, age over 60, age over 80, neurological disease, pulmonary 
disease, rheumatological disease, kidney disease, substance abuse (other than alcohol), metastatic 
tumour, hematological malignancy, ESBL carriage, gram stain result, E.coli urosepsis or CRP over 
100 mg/l on the first day. The odds ratios of death by day 7 for high cfDNA, qSOFA score ≥2 and 
both adjusted for these variables were 7.7 (95% CI 3.9 to 15.3), 11.6 (95% CI 5.5 to 24.3) and 
21.3(95% CI 10.5 to 43.5), respectively. In multivariable analysis, we included all statistically 
significantly associated variables in univariate analysis. QSOFA score ≥2, high cfDNA, qSOFA score 
≥2 combined with high cfDNA, cardiovascular disease and Pitt Bacteraemia Score ≥4 remained 
significant in this model.  
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Discussion 
The present study shows that qSOFA score and cfDNA identify patients with a high risk of death due 
to bacteraemia infection. In this study, 34 out of 128 (27%) patients with qSOFA score ≥2 in the ED 
had died by day 7. If the patients had both qSOFA score ≥2 and cfDNA of more than 1.69 µg/ml on 
day 0, 47% of them died. Thus, the combination of high cfDNA level and qSOFA score ≥2 elevated 
the risk of death by day 7 from 12-fold to 20-fold. 
QSOFA has recently been shown to predict organ failure and in-hospital mortality in 1009 patients 
with suspected infection [23]. Yet, the authors recommended the use of further confirmatory test. 
Given the present results, the combination of qSOFA score ≥2 and high cfDNA does not improve 
sensitivity in predicting death by day 7, but it could be an option to further improve specificity. As an 
illustration, we suggest a two-step approach where qSOFA score ≥2 is followed by cfDNA analysis: in 
the present material comprising 458 sepsis cases, qSOFA score ≥2 results in 128 cases at higher risk of 
death due to bacteraemia infection during the first week. Analysing the cfDNA of these 128 exposes 
57 cases with even higher 7-day mortality of 47%. Moreover, the turnaround time spent on laboratory 
analysis of cfDNA level was approximately 10 minutes (after plasma extraction). This does not make 
turnaround time a significant obstacle for clinical use, but due to the need for plasma extraction, no 
point-of-care test is yet available 
The Sepsis-3 task force did not find relevant change in predictive validity when lactate was added to 
qSOFA [24]. Clinicians will continue measuring lactate as the result is a numerical value rather than 
just the value of positive or negative. Especially high levels of lactate are seen in patients with severe 
infections, and the kinetics of lactate have been shown to have value in the prognosis of sepsis patients 
[25]. In this study, especially high levels of cfDNA were seen in patients with DIC that resulted in 
amputations. This is not surprising since a growing body of evidence suggests a role for cfDNA and 
DNA-binding proteins in the pathogenesis of DIC [14]. Because there were only few patients with 
DIC in our material, further studies are needed to establish cfDNA as an early marker for DIC. 
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Nevertheless, this finding also suggests that cfDNA could be an option to identify those patients with 
severe consequences of sepsis. 
The AUC of cfDNA in predicting death by day 7 and day 28 were 0.77 and 0.76, respectively. These 
are somewhat lower than in two studies done in ED with soluble urokinase-type plasminogen activator 
receptor (suPAR) [26, 27]. These studies had an AUC of 0.79 and 0.84 in predicting death by day 30. 
When using their cut-off values, suPAR seems to be more sensitive in predicting death (76% and 83% 
vs. 65%) and cfDNA has a slightly better specificity (69% and 76% vs. 78%). In another cfDNA study 
done by our group, these predictors are more or less the same as in the suPAR studies (AUC 0.84, 
sensitivity 83% and specificity 76%) [12]. As the biochemical mechanism of these two markers differs 
greatly, it is possible that these markers perform differently depending on the subgroups within septic 
patients. Cases with suspected DIC might be one subgroup where cfDNA could be of help. 
This study has some limitations. Our study was a single-centre tertiary hospital study comprising 
mostly community-onset infections. Furthermore, our material comprises only culture-positive cases, 
so one has to be cautious when extrapolating these results to culture-negative cases with infection. In 
addition, 167 of the culture-positive cases were excluded as the routine blood sample from day 0 was 
missed. However, the microbiological data of these missed cases were analysed and we did not find 
any differences that would have altered the findings of this study [20]. 
In line with previous studies [28-30], the results of the present study show that CRP-level has no value 
in predicting fatality. A high level of CRP (or leucocytes) is still an important sign for clinicians; at 
least they have to think could the patient have an infection or sepsis. When sepsis is suspected, a 
clinician in the ED has to decide, for example, whether the patient needs care in the ICU. A recent 
study suggested that only clinical impression of condition might be used to make this decision [31], 
but occasionally clinicians might need some extra help in making these decisions. Therefore, counting 
qSOFA score and measuring the level of cfDNA might help the decision-making process. 
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In conclusion, the present study shows that the combined information on qSOFA score and cfDNA 
can identify patients with the highest risk of death due to bacteraemia infection. These markers may 
find those patients admitted to ED with the highest need of care.  
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Table 1. Patient characteristics, clinical presentation and microbiological data of the study population 
  Data 
Demographic   
 Cases/Patients 481/469 
 Patients admitted twice/three times 10/1 
 Gender (female/male)) 228/253 
 Median age, y (range) 68 (16-95) 
Chronic medical condition n (%) 
 Coronary artery disease, chronic vascular disease or chronic 
heart failure 
155 (32) 
 Diabetes mellitus 137 (29) 
 Social or medical problems of alcohol abuse 49 (10) 
 Solid tumour with metastasis 55 (11) 
 Hematological malignancy 45 (9) 
Severity of the sepsis n (%) 
 Sepsis 481 (100) 
 Severe sepsis (≥1 organ failure) 145 (30) 
 Septic shock 36 (8) 
 qSOFA score ≥21 128 (28) 
 Case transferred from ED to ICU 44 (9) 
Site of infection n (%) 
 Urinary 134 (28) 
 Intra-abdominal 83 (17) 
 Skin, soft tissue and bones 71 (15) 
 Pulmonary 48 (10) 
 Unknown 116 (24) 
Causative organism n (%) 
Gram-positive  213 (44) 
 Staphylococcus aureus 71 (15) 
 Streptococcus pneumonia 46 (11) 
Gram-negative  219 (46) 
 E. coli 156 (32) 
                                                          
1 Data available on 458 cases 
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Others  46 (10) 
 Anaerobes 15 (3) 
 Fungi 1 (0.2) 
 Polymicrobial 30 (6) 
Day of case fatality n (%) 
 Days 0 to 7 44 (9) 
 Days 0 to 28 69 (14) 
 Days 0 to 90 97 (20) 
qSOFA, quick Sepsis-related Organ Failure Assessment; ED, Emergency Department; ICU, Intensive Care Unit  
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Table 2. Plasma cell free DNA (cfDNA) levels during days 0 to 4 after admission to emergency department in 
all cases and in relation to death by day 7 
Days after admission Plasma cfDNA (µg/ml), median (quartiles) p-values 
 All Non-survivors Survivors  
Day 0 1.38 (1.20-1.77) 2.02 (1.51-2.92) 1.35 (1.19-1.66) <0.001 
Day 1 1.36 (1.18-1.73) 2.20 (1.57-3.63) 1.33 (1.17-1.64) <0.001 
Day 2 1.35 (1.16-1.65) 1.87 (1.59-2.92) 1.33 (1.16-1.61) <0.001 
Day 3 1.33 (1.16-1.61) 1.81 (1.48-4.34) 1.32 (1.14-1.58) <0.001 
Day 4 1.35 (1.17-1.71) 1.66 (1.49-2.38) 1.33 (1.15-1.68) 0.017 
Maximum value 1.49 (1.28-1.91) 2.24 (1.56-4.55) 1.45 (1.27-1.81) <0.001 
cfDNA values available on 481 patients on day 0, 446 patients on day 1, 389 patients on day 2, 300 patients on 
day 3, 137 patients on day 4 and 481 patients on days 0 to 4 (maximum value). 
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Table 3. Diagnostic values of day 0 cfDNA with cut-off value of 1.69 µg/ml, qSOFA score ≥2 and both qSOFA score ≥2 and cfDNA>1.69 µg/ml in predicting death by day 7 
and day 28.  
 n (deceased/ 
survivors) 
Sensitivity 
(%) 
Specificity 
(%) 
Positive predictive 
value (%) 
Negative predictive 
value (%) 
Odds Ratio with 
95%CI 
AUC with 
95%CI 
p-values 
Death by day 7         
cfDNA >1.69 µg/ml 134 (31/103) 70.4 76.4 23.1 96.2 7.7 (3.9-15.3) 0.731 (0.65-0.82) <0.001 
qSOFA score ≥22 128 (34/94) 77.3 77.3 26.6 97.0 11.6 (5.5-24.3) 0.77 (0.70-0.85) <0.001 
cfDNA >1.69 µg/ml and 
qSOFA score ≥22 
57 (27/30) 61.4 92.8 47.4 95.8 20.3 (10.0-41.4)  0.77 (0.68-0.86) <0.001 
Death by day 28          
cfDNA >1.69 µg/ml 134 (45/89) 65.2 78.4 33.6 93.1 6.8 (3.9-11.8) 0.721 (0.65-0.79) <0.001 
qSOFA score ≥22 128 (45/83) 66.2 78.7 35.2 93.0 7.2 (4.1-12.6) 0.72 (0.66-0.79) <0.001 
cfDNA >1.69 µg/ml and 
qSOFA score ≥22 
57 (35/22) 51.5 94.3 61.4 91.8 17.7 (9.3-33.7) 0.73 (0.65-0.81) <0.001 
                                                          
1 See results for the AUC of cfDNA as a continuous variable 
2 Data available on 458 cases 
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Table 4. Day of admission plasma cell free DNA (cfDNA) values stratified by various demographic features, 
underlying conditions and severity of sepsis. 
 Plasma cfDNA (ug/ml) on day of admission to emergency 
department 
p-value 
 factor present, median 
(quartiles) 
factor absent, median 
(quartiles) 
 
Characteristics and 
underlying conditions 
   
Male 1.42 (1.24-1.85) 1.30 (1.16-1.64) 0.002 
Age over 60 years 1.39 (1.22-1.80) 1.32 (1.16-1.60) 0.035 
Age over 80 years 1.46 (1.25-1.89) 1.35 (1.18-1.69) 0.020 
Cardiovascular disease 1.40 (1.22-1.75) 1.36 (1.19-1.82) 0.822 
Diabetes any type 1.38 (1.18-1.70) 1.36 (1.20-1.77) 0.894 
Chronic kidney disease1 1.38 (1.26-1.73) 1.36 (1.19-1.77) 0.561 
Liver disease 1.91 (1.41-2.15) 1.35 (1.19-1.67) <0.001 
Alcohol abuse2 1.95 (1.47-2.38) 1.34 (1.18-1.64) <0.001 
Solid tumour with 
metastasis 
1.51 (1.20-1.97) 1.36 (1.19-1.71) 0.142 
Hematologic cancer 1.27 (1.12-1.68) 1.37 (1.22-1.76) 0.041 
Gram-positive bacteraemia3 1.35 (1.17-1.67) 1.38 (1.23-1.80) 0.180 
Polymicrobial infection 1.58 (1.25-2.13) 1.36 (1.19-1.75) 0.058 
Severity of sepsis    
qSOFA score ≥24 1.56 (1.26-2.20) 1.34 (1.16-1.64) <0.001 
Severe sepsis 1.61 (1.31-2.23) 1.31 (1.17-1.60) <0.001 
Septic shock 1.96 (1.32-2.83) 1.36 (1.19-1.70) <0.001 
                                                          
1 History of creatinine more than 120 µmol/l 
2 Social or medical problems of alcohol abuse in the past 12 months 
3 Excluding polymicrobial (n=30) and anaerobical (n=15) bacteraemia 
4 Data available on 458 cases 
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Admitted from ED to ICU 1.95 (1.40-2.89) 1.35 (1.19-1.69) <0.001 
Pitt Bacteraemia Score ≥45 1.83 (1.34-2.73) 1.35 (1.19-1.68) <0.001 
Death by day 7 2.02 (1.51-2.92) 1.35 (1.19-1.66) <0.001 
Death by day 28 1.95 (1.50-2.58) 1.33 (1.18-1.64) <0.001 
Abbreviations: ED, emergency department; ICU, intensive care unit  
                                                          
5 Data available on 474 cases 
21 
 
Figure 1. A line plot diagram showing cell free DNA (cfDNA) levels during days 0 to 4 after admission to 
emergency department in 44 patients who died by day 7 (black plots) and 437 survivors (open plots). One case 
with all cfDNA levels over 30 µg/ml excluded from the figure. *Cutoff, cfDNA value of 1.69 µg/ml had an 
optimal sensitivity of 70.4% and specificity of 76.4% in predicting day 7 mortality from the day 0 sample based 
on the AUC-ROC-analysis. 
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Figure 2. Receiver operating characteristic (ROC) curve on plasma cell-free DNA level, qSOFA score ≥2 and  
both cfDNA>1.69 µg/ml and qSOFA score  ≥2 measured on day of admission to the Emergency Department in 
relation to case fatality by day 7.  
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Figure 3. Cumulative day 28 survival in culture-positive cases with A) maximum plasma cell free DNA (cfDNA) > 1.69 µg/ml compared with those with cfDNA ≤ 1.69 
µg/ml, B) qSOFA score ≥2 compared with those with qSOFA score <2 and C) cfDNA >1.69 and qSOFA score ≥2 compared with those with cfDNA≤ 1.69 µg/ml and 
qSOFA<2. The survival curve was calculated using the Kaplan-Meier method, and survival differences between groups were compared by log-rank test. 
  
 
